Purpose: Current and future treatment modalities for Clostridium difficile-associated disease (CDAD) are reviewed. Conclusion: CDAD is a major concern for health care systems and clinicians.

Bezlotoxumab, an IgG1 monoclonal antibody targeting C. difficile toxin B, is recommended for high-risk patients to prevent further recurrences. While the addition of bezlotoxumab has shown benefit in ...

The ability to perceive the bitter taste is thought to have evolved as a protective mechanism, signaling the presence of toxins in foods. When we bite bitter compounds, TAS2Rs respond by ...

One of these, mainly needed for Rompopolo gear – as well as Rathian and Gypceros armor sets – is Toxin Sacs. Toxin Sacs are the organs of the monster who’s dropped them, often packed with ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

difficile toxins. Accordingly, we identified that both TcdA and TcdB stimulated the expression of P2X7R in EGCs. P2X7R has been extensively investigated due to its upregulation in a variety of ...

Clostridium difficile (C ... of antibiotics (Johnson et al., 1999). C. difficile, transmitted in humans through the fecal-oral route, is an anaerobic Gram-positive, spore-forming bacillus that ...